{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:20:54Z","timestamp":1791829254722,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Program","doi-asserted-by":"publisher","award":["21ZYJDJC00020"],"award-info":[{"award-number":["21ZYJDJC00020"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"State Administration of Traditional Chinese Medicine of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.ejpb.2023.05.017","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T20:47:18Z","timestamp":1684788438000},"page":"243-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Baicalin\/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-4577","authenticated-orcid":false,"given":"Dongli","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Pi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4449-6725","authenticated-orcid":false,"given":"Zhidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.05.017_b0005","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0010","doi-asserted-by":"crossref","unstructured":"G. Raghu, M. Remy-Jardin, J.L. Myers, L. Richeldi, C.J. Ryerson, D.J. Lederer, Juergen Behr, Vincent Cottin, Sonye K. Danoff, Ferran Morell, Kevin R. Flaherty, Athol Wells, Fernando J. Martinez, Arata Azuma, Thomas J. Bice, Demosthenes Bouros, Kevin K. Brown, Harold R. Collard, Abhijit Duggal, Liam Galvin, Yoshikazu Inoue, R. Gisli Jenkins, Takeshi Johkoh, Ella A. Kazerooni, Masanori Kitaichi, Shandra L. Knight, George Mansour, Andrew G. Nicholson, Sudhakar N. J. Pipavath, Ivette Buend\u00eda-Rold\u00e1n, Mois\u00e9s Selman, William D. Travis, Simon L. F. Walsh, and Kevin C. Wilson, Diagnosis of idiopathic pulmonary fibrosis. an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care. Med. 198(2018) e44-e68.","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"10.1016\/j.ejpb.2023.05.017_b0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1165\/rcmb.2016-0121TR","article-title":"Immune mechanisms in pulmonary fibrosis","volume":"55","author":"Kolahian","year":"2016","journal-title":"Am. J. Respir. Cell. Mol. Biol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0020","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1164\/rccm.201709-1823OC","article-title":"Dicer1 deficiency in the idiopathic pulmonary fibrosis fibroblastic focus promotes fibrosis by suppressing microRNA biogenesis","volume":"198","author":"Herrera","year":"2018","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7113-8_1","article-title":"Human fibrotic diseases: current challenges in fibrosis research","volume":"1627","author":"Rosenbloom","year":"2017","journal-title":"Methods. Mol. Biol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0030","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cell.2021.01.020","article-title":"Progressive pulmonary fibrosis is caused by elevated mechanical tension on alveolar stem cell","volume":"184","author":"Wu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejpb.2023.05.017_b0035","first-page":"1","article-title":"Lung transplantation in idiopathic pulmonary fibrosis","volume":"6","author":"Laporta","year":"2018","journal-title":"Med. Sci."},{"key":"10.1016\/j.ejpb.2023.05.017_b0040","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am. J. Respir. Crit. Care. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1021\/acs.jmedchem.6b00935","article-title":"Idiopathic Pulmonary fibrosis: current status, recent progress, and emerging targets","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejpb.2023.05.017_b0050","unstructured":"Nature website. https:\/\/www.nature.com\/collections\/aeicdaeegi."},{"key":"10.1016\/j.ejpb.2023.05.017_b0055","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMp1901233","article-title":"A temporizing solution to \u201cArtemisinin Resistance\u201d","volume":"380","author":"Wang","year":"2019","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0060","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1473-3099(19)30535-3","article-title":"Suboptimal dosing triggers artemisinin partner drug resistance","volume":"19","author":"Wang","year":"2019","journal-title":"Lancet. Infect. Dis."},{"key":"10.1016\/j.ejpb.2023.05.017_b0065","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1039\/C5NP00133A","article-title":"Artemisinin, a miracle of traditional Chinese medicine","volume":"32","author":"Kong","year":"2015","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejpb.2023.05.017_b0070","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2468-1253(19)30409-1","article-title":"Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study","volume":"5","author":"Chen","year":"2020","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0075","doi-asserted-by":"crossref","first-page":"111072","DOI":"10.1016\/j.biopha.2020.111072","article-title":"Traditional Chinese Medicine combined with pulmonary drug delivery system and idiopathic pulmonary fibrosis: Rationale and therapeutic potential","volume":"133","author":"Zhang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2023.05.017_b0080","first-page":"1145","article-title":"Research progress on the inflammatory mechanism of chronic obstructive pulmonary disease and the therapeutic effect of traditional Chinese medicine monomers","volume":"29","author":"Li","year":"2018","journal-title":"China. Pharmacy."},{"key":"10.1016\/j.ejpb.2023.05.017_b0085","first-page":"120","article-title":"Research progress on therapeutic drugs for silicotic pulmonary fibrosis","volume":"31","author":"Guo","year":"2018","journal-title":"Chin. J. Ind. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0090","first-page":"1382","article-title":"Impact of baicalin on oxidative stress, and inflammatory cell in pulmonary fibrosis","volume":"35","author":"Wang","year":"2017","journal-title":"Chin. Archives. Trad. Chin. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0095","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12890-016-0294-1","article-title":"Baicalin attenuates bleomycin-induced pulmonary fibrosis via adenosine A2a receptor related TGF\u2013\u03b21-induced ERK1\/2 signaling pathway","volume":"16","author":"Huang","year":"2016","journal-title":"BMC. Pulm. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0100","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.autrev.2014.08.028","article-title":"Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis","volume":"13","author":"Zhang","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.ejpb.2023.05.017_b0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.pupt.2010.05.004","article-title":"Baicalin attenuates inflammation by inhibiting NF-kappa B activation in cigarette smoke induced inflammatory models","volume":"23","author":"Zeng","year":"2010","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2023.05.017_b0110","first-page":"1481","article-title":"Discovery of intervention effect of Chinese herbal formulas on COVID-19 pulmonary fibrosis treated by VEGFR and FGFR inhibitors","volume":"45","author":"Bian","year":"2020","journal-title":"China J. Chin. Mater. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0115","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejphar.2016.02.030","article-title":"Ambroxol inhalation ameliorates LPS-induced airway inflammation and mucus secretion through the extracellular signal-regulated kinase 1\/2 signaling pathway","volume":"775","author":"Zhang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0120","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/17425255.4.8.1119","article-title":"Ambroxol in the 21st century: pharmacological and clinical update","volume":"4","author":"Malerba","year":"2008","journal-title":"Expert. Opin. Drug. Met."},{"key":"10.1016\/j.ejpb.2023.05.017_b0125","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1755-5949.2007.00032.x","article-title":"Ambroxol: a CNS drug?","volume":"14","author":"Weiser","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejpb.2023.05.017_b0130","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/sj.bjp.0705497","article-title":"In vitro inhibition of human neutrophil histotoxicity by ambroxol: evidence for a multistep mechanism","volume":"140","author":"Ottonello","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S2213-2600(14)70232-2","article-title":"Combination therapy: the future of management for idiopathic pulmonary fibrosis?","volume":"2","author":"Wuyts","year":"2014","journal-title":"Lancet. Respir. Med."},{"key":"10.1016\/j.ejpb.2023.05.017_b0140","series-title":"Lung anatomy and physiology and their implications for pulmonary drug delivery","author":"Verma","year":"2015"},{"key":"10.1016\/j.ejpb.2023.05.017_b0145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2022.05.039","article-title":"Novel drug delivery systems and disease models for pulmonary fibrosis","volume":"348","author":"Li","year":"2022","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2023.05.017_b0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.addr.2014.05.017","article-title":"Delivery strategies for sustained drug release in the lungs","volume":"75","author":"Loira-Pastoriza","year":"2014","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.ejpb.2023.05.017_b0155","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/03639045.2017.1313858","article-title":"A review of co-milling techniques for the production of high dose dry powder inhaler formulation","volume":"43","author":"Lau","year":"2017","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2023.05.017_b0160","doi-asserted-by":"crossref","first-page":"108601","DOI":"10.1016\/j.biopha.2019.108601","article-title":"Recent advances in aerosolised drug delivery","volume":"112","author":"Chandel","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejpb.2023.05.017_b0165","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1080\/07373937.2017.1281291","article-title":"Spray drying of mannitol carrier particles with defined morphology and flow characteristics for dry powder inhalation","volume":"35","author":"Mo\u00a8nckedieck","year":"2017","journal-title":"Dry. Technol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0170","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11095-017-2334-9","article-title":"Physico-chemical properties, aerosolization and dissolution of co-Spray dried azithromycin particles with l-leucine for inhalation","volume":"35","author":"Mangal","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.05.017_b0175","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2019.03.004","article-title":"A Design of experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose\/leucine formulations with application in pulmonary delivery","volume":"562","author":"Focaroli","year":"2019","journal-title":"Int. J. Pharmaceut."},{"key":"10.1016\/j.ejpb.2023.05.017_b0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejpb.2016.02.010","article-title":"L-leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders","volume":"102","author":"Li","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.05.017_b0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1089\/jamp.2019.1538","article-title":"Salvia miltiorrhiza physicochemical and pharmacokinetic evaluation of spray-dried coformulation of polyphenolic acid and l-leucine with improved bioavailability","volume":"33","author":"Lu","year":"2020","journal-title":"J. Aerosol. Med. Pulm. Drug. Deliv."},{"key":"10.1016\/j.ejpb.2023.05.017_b0190","first-page":"447","article-title":"Salvianolic acid B dry powder inhaler for the treatment of idiopathic pulmonary fibrosis","volume":"17","author":"Lu","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.05.017_b0195","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejps.2010.04.012","article-title":"Understanding the influence of powder flowability, fluidization and de-agglomeration characteristics on the aerosolization of pharmaceutical model powders","volume":"40","author":"Zhou","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.05.017_b0200","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.drudis.2019.09.023","article-title":"Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery","volume":"25","author":"Liu","year":"2020","journal-title":"Drug. Discov. Today."},{"key":"10.1016\/j.ejpb.2023.05.017_b0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2019.01.018","article-title":"D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation","volume":"130","author":"Schoubben","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.05.017_b0210","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/pharmaceutics12010024","article-title":"Dispersibility and storage stability optimization of high dose isoniazid dry powder inhalation formulations with l-leucine or trileucine","volume":"12","author":"Sibum","year":"2019","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejpb.2023.05.017_b0215","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.drudis.2014.09.020","article-title":"Recent advances in controlled pulmonary drug delivery","volume":"20","author":"Liang","year":"2015","journal-title":"Drug. Discov. Today."},{"key":"10.1016\/j.ejpb.2023.05.017_b0220","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s13346-017-0462-8","article-title":"Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance of salbutamol sulfate from DPI formulations","volume":"8","author":"Molina","year":"2018","journal-title":"Drug. Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2023.05.017_b0225","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.powtec.2012.02.047","article-title":"Improvement of the dispersibility of spray-dried budesonide powders using leucine in an ethanol-water cosolvent system","volume":"236","author":"Mohammed","year":"2013","journal-title":"Powder. Technol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0230","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jchromb.2015.01.018","article-title":"Profiling and identification of the metabolites of baicalin and study on their tissue distribution in rats by ultra-high-performance liquid chromatography with linear ion trap-Orbitrap mass spectrometer","volume":"985","author":"Zhang","year":"2015","journal-title":"J. Chromatogr. B."},{"key":"10.1016\/j.ejpb.2023.05.017_b0235","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/00498251003663724","article-title":"Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives","volume":"40","author":"Srinivas","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejpb.2023.05.017_b0240","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s13318-018-0509-3","article-title":"Pharmacokinetics and Bioavailability Enhancement of Baicalin: A Review","volume":"44","author":"Huang","year":"2019","journal-title":"Eur. J. Drug. Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2023.05.017_b0245","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/jps.21529","article-title":"Pulmonary selectivity and local pharmacokinetics of ambroxol hydrochloride dry powder inhalation in rat","volume":"98","author":"Ren","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.05.017_b0250","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(17)30866-8","article-title":"Idiopathic pulmonary fibrosis","volume":"389","author":"Richeldi","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.ejpb.2023.05.017_b0255","doi-asserted-by":"crossref","first-page":"1801118","DOI":"10.1183\/13993003.01118-2018","article-title":"Myeloperoxidase oxidation of methionine associates with early cystic fibrosis lung disease","volume":"52","author":"Chandler","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejpb.2023.05.017_b0260","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3389\/fphar.2017.00904","article-title":"GHK peptide inhibits bleomycin-induced pulmonary fibrosis in mice by suppressing TGF\u03b21\/Smad-mediated epithelial-to-mesenchymal transition","volume":"8","author":"Zhou","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0265","doi-asserted-by":"crossref","first-page":"114356","DOI":"10.1016\/j.bcp.2020.114356","article-title":"Overcoming interferon (IFN)-\u03b3 resistance ameliorates transforming growth factor (TGF)-\u03b2-mediated lung fibroblast-to-myofibroblast transition and bleomycin-induced pulmonary fibrosis","volume":"183","author":"Chang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejpb.2023.05.017_b0270","doi-asserted-by":"crossref","first-page":"117139","DOI":"10.1016\/j.lfs.2019.117139","article-title":"Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways","volume":"241","author":"Ma","year":"2020","journal-title":"Life. Sci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112300139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112300139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:54:01Z","timestamp":1760547241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112300139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":54,"alternative-id":["S093964112300139X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.05.017","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baicalin\/ambroxol hydrochloride combined dry powder inhalation formulation targeting lung delivery for treatment of idiopathic pulmonary fibrosis: Fabrication, characterization, pharmacokinetics, and pharmacodynamics","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}